Scientific Publications

Recent publications on Crucell’s core technologies and vaccine/antibody/ protein development programs are listed below. The articles have been grouped according to the technologies used. Please click on any of these to access the abstracts of the articles:

• Crucell-related articles
• PER.C6^®-related articles
• AdVac^®-related articles
• Mabstract^®-related articles

For more Crucell scientific papers please use search word ‘Crucell’ at the website of PubMed.

Crucell-related articles

• Damian C. Ekiert, Gira Bhabha, Marc-André Elsliger, Robert H. E. Friesen, Mandy Jongeneelen, Mark Throsby, Jaap Goudsmit, Ian A. Wilson. Antibody Recognition of a Highly Conserved Influenza Virus Epitope. Science 2009 EPub February 26.

• Mark Throsby, Edward van den Brink, Mandy Jongeneelen, Leo L. M. Poon, Philippe Alard, Lisette Cornelissen, Arjen Bakker, Freek Cox, Els van Deventer, Yi Guan, Jindrich Cinatl, Jan ter Meulen, Ignace Lasters, Rita Carsetti, Malik Peiris, John de Kruif, Jaap Goudsmit. Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells. PLoS ONE 2008. 3(12):e3942. Epub 2008 Dec 16

• Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, Lagerwerf F, Worst S, van Corven E, Kostense S, Hartmann K, Weverling GJ, Uytdehaag F, Herzog C, Briggs DJ, Rupprecht CE, Grimaldi R, Goudsmit J. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008 Nov 5;26(47):5922-7. Epub 2008 Sep 17.

• Künzi V, Dornseiff M, Horwath J, Hartmann K. Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine 2009 Feb 18;27(8):1261-5. Epub 2008 Dec 27.

• Katarina Radosevic, Ariane Rodriguez, Ratna Mintardjo, Dennis Tax, Karin Lövgren Bengtsson, Catherine Thompson, Maria Zambon, Gerrit Jan Weverling, Fons UytdeHaag, Jaap Goudsmit. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine 26 2008. 3640–3646

• Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infect Immun 2008 Apr;76(4):1709-18. Epub 2008 Jan 22.

• ter Meulen J. Monoclonal antibodies for prophylaxis and therapy of infectious diseases. Expert Opin Emerg Drugs. 2007 Nov;12(4):525-40.

• Peter Abbink, Angelique A.C. Lemckert, Bonnie A. Ewald, Diana M. Lynch, Matthew Denholtz, Shirley Smits, Lennart Holterman, Irma Damen, Ronald Vogels, Anna R. Thorner, Kara L. O’Brien, Angela Carville, Keith G. Mansfield, Jaap Goudsmit, Menzo J.E. Havenga, Dan H. Barouch. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. J. Virol. 2007. doi:10.1128/JVI.02696-06

• Pfister M.; Kursteiner O.; Hilfiker H.; Favre D.; Durrere P.; Ennaji A.; L'Age-Stehr J.; Kaufhold A.; Herzog C. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg. 2005. 72(3), 339-346.

• Bogaards, J.A.; Ballegooijen, W.M.V.; Jan Weverling, G.; Boerlijst, M.C.; Goudsmit, J. Is population-level perversity a likely outcome of mass vaccination against HIV? Lancet Infect Dis. 2005. 5(5), 254.
• Bakker A.B.; van den Oudenrijn S.; Bakker A.Q.; Feller N.; van Meijer M.; Bia J.A.; Jongeneelen M.A.; Visser T.J.; Bijl N.; Geuijen C.A; Marissen W.E.; Radosevic K.; Throsby M.; Schuurhuis G.J.; Ossenkoppele G.J.; de Kruif J.; Goudsmit J.; Kruisbeek A.M. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004. 64(22), 8443-8450.
• Lemckert A.A.; Goudsmit J.; Barouch D.H. Challenges in the search for an HIV vaccine. Eur J Epidemiol. 2004. 19(6), 513-516.

PER.C6®-related articles

• Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J. Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity. Biotechnol Bioeng 2008 Jun 1;100(2):273-83

• Marzio G.; Kerkvliet E; J.A. Bogaards, S. Koelewijn, A. de Groot,

  L. Gijsbers; G.J. Weverling; R. Vogels; M. Havenga; J. Custers;

  M.G. Pau; J.Y. Guichoux; J. Lewis; J. Goudsmit. A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells Vaccine 25. 2007. 2228–2237

• Havenga, M.; Vogels, R.; Zuijdgeest, D.; Radosevic, K.; Mueller, S.; Sieuwerts, M.; Weichold, F.; Damen, I.; Kaspers, J.; Lemckert, A.; Meerendonk, M.van; Vlugt, R. Van Der; Holterman, L.; Hone, D.; Skeiky, Y.; Mintardjo, R.; Gillissen, G.; Barouch, D.; Sadoff, J.; Goudsmit, J. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol. 2006. 87(Pt 8), 2135-2143.

• Kapteyn, J.C.; Saidi, M.D.; Kijkstra, R.; Kars, C.; Tjon, J.C.; Weverling, G.J.; Vocht, M.L.D.; Kompier, R.; Montfort, B.A.V.; Guichoux, J.Y.; Goudsmit, J.; Lagerwerf, F.M. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine. 2006. 24(16), 3137-3144.
• Ledwith, B.J.; Lanning, C.L.; Gumprecht, L.A.; Anderson, C.A.; Coleman, J.B.; Gatto, N.T.; Balasubramanian, G.; Farris, G.M.; Kemp, R.K.; Harper, L.B.; Barnum, A.B.; Pacchione, S.J.; Mauer, K.L.; Troilo, P.F.; Brown, E.R.; Wolf, J.J.; Lebronl, J.A.; Lewis, J.A.; Nichols, W.W. Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol (Basel). 2006. 123, 251-263; discussion 265-266.
• Lewis, J.A.; Brown, E.L.; Duncan, P.A. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel). 2006. 123, 165-176; discussion 183-197.
• Maranga, L.; Aunins, J.G.; Zhou, W. Characterization of changes in PER.C6 trade mark cellular metabolism during growth and propagation of a replication-deficient adenovirus vector. Biotechnol Bioeng. 2005. 90(5), 645-655.
• Kwaks, T.H.; Sewalt, R.G.; Van Blokland, R.; Siersma, T.J.; Kasiem, M.; Kelder, A.; Otte, A.P. Targeting of a histone acetyltransferase domain to a promoter enhances protein expression levels in mammalian cells. J Biotechnol. 2005. 115(1), 35-46.
• Gijsbers, L.; Koel, B.; Weggeman, M.; Goudsmit, J.; Havenga, M.; Marzio, G. Quantification of residual host cell DNA in adenoviral vectors produced on PER.C6® cells. Hum Gene Ther. 2005. 16(3), 393-398.
• Murakami P.; Havenga M.; Fawaz F.; Vogels R.; Marzio G.; Pungor E.; Files J.; Do L.; Goudsmit J.; McCaman M. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J Virol. 2004. 78(12), 6200-6208.
• Jones D.; Kroos N.; Anema R.; van Montfoort B.; Vooys A.; van der Kraats S.; van der Helm E.; Smits S.; Schouten J.; Brouwer K.; Lagerwerf F.; van Berkel P.; Opstelten D.J.; Logtenberg T.; Bout A. High Level expression of recombinant IgG in the human cell line PER.C6™. Biotechnol Prog. 2003. 19(1), 163-168.
• Kirschweger G. Crucell: biopharmaceuticals -- as human as they get. Mol Ther. 2003. 7(1), 5-6.
• Nichols W.; Lardenoije R.; Ledwith B.; Brower K.; Manam S.; Vogels R.; Kaslow D.; Zuidgeest D.; Bett A.; Chen L.; van der Kaaden M.; Galloway S.; Hill R.; Machotka S.; Anderson C.; Lewis J.; Martinez D.; Lebron J.; Russo C.; Valerio D.; Bout A. Propagation of Adenoviral Vectors: Use of PER.C6^® Cells. 2002. In "Adenoviral Vectors for Gene Therapy", pp. 129-166. Elsevier Science, USA.

AdVac®-related articles

• Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 2008 Jun 2;26(23):2818-23. Epub 2008 Apr 16.

• Ophorst, O.J.; Radosevic, K.; Havenga, M.J.; Pau, M.G.; Holterman, L.; Berkhout, B.; Goudsmit, J.; Tsuji, M. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun. 2006. 74, 313-320.
• Roberts, D.M.; Nanda, A.; Havenga, M.J.; Abbink, P.; Lynch, D.M.; Ewald, B.A.; Liu, J.; Thorner, A.R.; Swanson, P.E.; Gorgone, D.A.; Lifton, M.A.; Lemckert, A.A.; Holterman, L.; Chen, B.; Dilraj, A.; Carville, A.; Mansfield, K.G.; Goudsmit, J.; Barouch, D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006. 441, 239-243.
• Sumida, S.M., Truitt, D.M., Lemckert, A.A., Vogels, R., Custers, J.H., Addo, M.M., Lockman, S., Peter, T., Peyerl, F.W., Kishko, M.G., Jackson, S.S., Gorgone, D.A., Lifton, M.A., Essex, M., Walker, B.D., Goudsmit, J., Havenga, M.J., And Barouch, D.H. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein. J Immunol. 2005. 174(11), 7179-7185
• Lusky, M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther. 2005. 16(3), 281-291.
• Heppner D.G. Jr; Kester K.E.; Ockenhouse C.F.; Tornieporth N; Ofori O; Lyon J.A.; Stewart V.A.; Dubois P.; Lanar D.E.; Krzych U.; Moris P.; Angov E.; Cummings J.F.; Leach A.; Hall B.T.; Dutta S.; Schwenk R.; Hillier C.; Barbosa A.; Ware L.A.; Nair L.; Darko C.A.; Withers M.R.; Ogutu B.; Polhemus M.E.; Fukuda M.; Pichyangkul S.; Gettyacamin M.; Diggs C.; Soisson L.; Milman J.; Dubois M.C.; Garcon N.; Tucker K.; Wittes J.; Plowe C.V.; Thera M.A.; Duombo O.K.; Pau M.G.; Goudsmit J.; Ballou W.R.; Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005. 23(17-18), 2243-2250.
• Goncalves, M.; Van Nierop, G.; Tijssen, M.; Lefesvre, P.; Knaan-Shanzer, S.; Van Der Velde, I.; Van Bekkum, D.; Valerio, D.; De Vries, A. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol. 2005. 79(5), 3146-3162
• Eleveld-Trancikova, D.; Triantis, V.; Moulin, V.; Looman, M.; Wijers, M.; Fransen, J.; Lemckert, A.; Havenga, M.; Figdor, C.; Janssen, R.; Adema, G. The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum. J Leukoc Biol. 2005. 77(3), 337-34
• Holterman L.; Vogels R.; van der Vlugt R.; Sieuwerts M.; Grimbergen J.; Kaspers J.; Geelen E.; van der Helm E.; Lemckert A.; Gillissen G.; Verhaagh S.; Custers J.; Zuijdgeest D.; Berkhout B.; Bakker M.; Quax P.; Goudsmit J.; Havenga M. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol. 2004. 78(23), 13207-13215.
• Kostense S.; Koudstaal W.; Sprangers M.; Weverling G.J.; Penders G.; Helmus N.; Vogels R.; Bakker M.; Berkhout B.; Havenga M.; Goudsmit J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004. 18(8), 1213-1216.
• Mercier S.; Verhaagh S.; Goudsmit J.; Lemckert A.; Monteil M.; Havenga M.; Eloit M. Adenovirus fibre exchange alters cell tropism in vitro but not transgene-specific T CD8+ immune responses in vivo. J Gen Virol. 2004. 85(Pt 5), 1227-1236.
• Ophorst O.J.; Kostense S.; Goudsmit J.; De Swart R.L.; Verhaagh S.; Zakhartchouk A.; Van Meijer M.; Sprangers M.; Van Amerongen G.; Yuksel S.; Osterhaus A.D.; Havenga M.J. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine. 2004. 22(23-24), 3035-3044.
• Slager E.H.; van der Minne C.E.; Goudsmit J.; van Oers J.M.; Kostense S.; Havenga M.J.; Osanto S.; Griffioen M. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004. 11(3), 227-236.
• Sumida S.M.; Truitt D.M.; Kishko M.G.; Arthur J.C.; Jackson S.S.; Gorgone D.A.; Lifton M.A.; Koudstaal W.; Pau M.G.; Kostense S.; Havenga M.J.; Goudsmit J.; Letvin N.L.;, Barouch D.H. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. 2004. 78(6), 2666-2673.
• Barouch D.H.; Pau M.G.; Custers J.H.; Koudstaal W.; Kostense S.; Havenga M.J.; Truitt D.M.; Sumida S.M.; Kishko M.G.; Arthur J.C.; Korioth-Schmitz B.; Newberg M.H.; Gorgone D.A.; Lifton M.A.; Panicali D.L.; Nabel G.J.; Letvin N.L.; Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-ad5 immunity. J Immun. 2004. 172(10), 6290-6297.
• Vogels R.; Zuijdgeest D.; van Rijsoever R.; Hartkoorn E.; Damen I.; de Bethune M.P.; Kostense S.; Penders G.; Helmus N.; Koudstaal W.; Cecchini M.; Wetterwald A.; Sprangers M.; Lemckert A.; Ophorst O.; Koel B.; van Meerendonk M.; Quax P.; Panitti L.; Grimbergen J.; Bout A.; Goudsmit J.; Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003. 77(15), 8263-8271.
• Havenga M.; Lemckert A.; Ophorst O.; van Meijer M.; Germeraad W.; Grimbergen J.; van den Doel M.; Vogels R.; van Deutekom J.; Janson A.; de Bruijn J.; Uytdehaag F.; Quax P.; Logtenberg T.; Methali, M.; Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol. 2002. 76(9), 4612-4620.